Damora Therapeutics (DMRA) Short-term Investments (2021 - 2024)

Damora Therapeutics (DMRA) has 4 years of Short-term Investments data on file, last reported at $6.1 million in Q1 2024.

• For the quarter ending Q1 2024, Short-term Investments fell 78.42% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2024 stood at $6.1 million (down 78.42% YoY), and the FY2023 full-year result was $11.7 million, down 57.41% from the prior year.
• Short-term Investments for Q1 2024 stood at $6.1 million, down from $11.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $49.2 million in Q2 2022 and bottomed at $6.1 million in Q1 2024.
• The 4-year median for Short-term Investments is $33.2 million (2021), against an average of $31.1 million.
• The widest annual swing landed in 2022, when Short-term Investments jumped 48.39%; it then slumped 78.42% in 2024.
• A 4-year view of Short-term Investments shows it stood at $37.6 million in 2021, then fell by 27.08% to $27.4 million in 2022, then sank by 57.41% to $11.7 million in 2023, then plunged by 47.97% to $6.1 million in 2024.
• The last three Short-term Investments figures came in at $6.1 million (Q1 2024), $11.7 million (Q4 2023), and $21.1 million (Q3 2023), per Business Quant data.

Peer Comparison